Mutations in Ribosomal Protein L16 Conferring Reduced Susceptibility to Evernimicin (SCH27899): Implications for Mechanism of Action

Antimicrobial Agents and Chemotherapy- United States

doi 10.1128/aac.44.3.732-738.2000

Full Text

Abstract

Available in

Categories

Infectious Diseases

Date

March 1, 2000

Authors

Peter V. Adrian

Roberta S. Hare

Keith P. Klugman

Publisher

American Society for Microbiology

Related search

Mutations in Ribosomal Protein L16 and in 23S rRNA in Enterococcus Strains for Which Evernimicin MICs Differ

Antimicrobial Agents and Chemotherapy

Infectious Diseases

English

Clinical Isolates of Staphylococcus Aureus With Ribosomal Mutations Conferring Resistance to Macrolides

Antimicrobial Agents and Chemotherapy

Infectious Diseases

English

A Novel Site of Antibiotic Action in the Ribosome: Interaction of Evernimicin With the Large Ribosomal Subunit

Proceedings of the National Academy of Sciences of the United States of America

Multidisciplinary

English

Mutations in the Ribosomal Protein Gene RPL10 Suggest a Novel Modulating Disease Mechanism for Autism

Molecular Psychiatry

Molecular Neuroscience

Molecular Biology

English

Role of Ribosomal Protein Mutations in Tumor Development (Review)

International Journal of Oncology

Cancer Research

English

Analysis of Ribosomal Protein Gene Structures: Implications for Intron Evolution

Molecular Biology

Cancer Research

English

Pyrosequencing to Detect Mutations in FKS1 That Confer Reduced Echinocandin Susceptibility in Candida Albicans

Antimicrobial Agents and Chemotherapy

Infectious Diseases

English

Limited ERG11 Mutations Identified in Isolates of Candida Auris Directly Contribute to Reduced Azole Susceptibility

Antimicrobial Agents and Chemotherapy

Infectious Diseases

English

Characterization of Mutations Conferring Resistance to Rifampicin in Mycobacterium Tuberculosis Clinical Strains

Antimicrobial Agents and Chemotherapy

Infectious Diseases

English